Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Current Leases (2023 - 2025)

Zenas BioPharma has reported Current Leases over the past 3 years, most recently at $1.1 million for Q4 2025.

  • Quarterly results put Current Leases at $1.1 million for Q4 2025, up 42.04% from a year ago — trailing twelve months through Dec 2025 was $1.1 million (up 42.04% YoY), and the annual figure for FY2025 was $1.1 million, up 42.04%.
  • Current Leases for Q4 2025 was $1.1 million at Zenas BioPharma, up from $618000.0 in the prior quarter.
  • Over the last five years, Current Leases for ZBIO hit a ceiling of $1.1 million in Q4 2025 and a floor of $384000.0 in Q3 2024.
  • Median Current Leases over the past 3 years was $785000.0 (2024), compared with a mean of $737000.0.
  • Biggest five-year swings in Current Leases: skyrocketed 41.19% in 2024 and later skyrocketed 60.94% in 2025.
  • Zenas BioPharma's Current Leases stood at $556000.0 in 2023, then skyrocketed by 41.19% to $785000.0 in 2024, then surged by 42.04% to $1.1 million in 2025.
  • The last three reported values for Current Leases were $1.1 million (Q4 2025), $618000.0 (Q3 2025), and $793000.0 (Q2 2025) per Business Quant data.